公开(公告)号：US11999798B2

公开(公告)日：2024-06-04

申请号：US17404459

申请日：2021-08-17

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Dirk Voelkel ,  Robert Pachlinger ,  Hanspeter Rottensteiner ,  Alfred Weber ,  Andrea Engelmaier

IPC: C07K16/36 ,  C07K16/00 ,  G01N33/573 ,  G01N33/86

CPC classification number: C07K16/36 ,  C07K16/005 ,  G01N33/573 ,  G01N33/86 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/21 ,  C07K2319/43 ,  G01N2333/9645

Abstract: Provided herein are anti-Factor IX Padua binding constructs, e.g., antibodies and antigen-binding fragments thereof. Related polypeptides, conjugates and kits are also provided. The inventions may be used in methods of detecting Factor IX Padua in a sample.

公开(公告)号：US11098132B2

公开(公告)日：2021-08-24

申请号：US16301962

申请日：2017-05-16

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Dirk Voelkel ,  Robert Pachlinger ,  Hanspeter Rottensteiner ,  Alfred Weber ,  Andrea Engelmaier

IPC: C07K16/36 ,  G01N33/573 ,  C07K16/00 ,  G01N33/86

Abstract: Provided herein are anti-Factor IX Padua binding constructs, e.g., antibodies and antigen-binding fragments thereof. Related polypeptides, conjugates and kits are also provided. The inventions may be used in methods of detecting Factor IX Padua in a sample.

公开(公告)号：US20240117009A1

公开(公告)日：2024-04-11

申请号：US18545528

申请日：2023-12-19

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Wolfgang Teschner ,  Hans-Peter Schwarz ,  Ruth Madlener ,  Sonja Svatos ,  Azra Pljevljakovic ,  Alfred Weber

IPC: C07K16/06 ,  A61K9/00 ,  A61K9/08 ,  A61K35/16 ,  A61K38/17 ,  A61K39/395 ,  A61K47/18 ,  B01D15/12 ,  B01D15/36 ,  B01D15/42 ,  C07K1/30 ,  C07K1/36

CPC classification number: C07K16/065 ,  A61K9/0019 ,  A61K9/08 ,  A61K35/16 ,  A61K38/1709 ,  A61K39/39525 ,  A61K47/183 ,  B01D15/12 ,  B01D15/362 ,  B01D15/363 ,  B01D15/424 ,  C07K1/30 ,  C07K1/36

Abstract: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.

公开(公告)号：US11891431B2

公开(公告)日：2024-02-06

申请号：US17103618

申请日：2020-11-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Wolfgang Teschner ,  Hans-Peter Schwarz ,  Ruth Madlener ,  Sonja Svatos ,  Azra Pljevljakovic ,  Alfred Weber

IPC: C07K16/06 ,  A61K9/00 ,  A61K9/08 ,  A61K38/17 ,  A61K47/18 ,  C07K1/30 ,  C07K1/36 ,  A61K39/395 ,  A61K35/16 ,  B01D15/12 ,  B01D15/36 ,  B01D15/42

CPC classification number: C07K16/065 ,  A61K9/0019 ,  A61K9/08 ,  A61K35/16 ,  A61K38/1709 ,  A61K39/39525 ,  A61K47/183 ,  B01D15/12 ,  B01D15/362 ,  B01D15/363 ,  B01D15/424 ,  C07K1/30 ,  C07K1/36

Abstract: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.

公开(公告)号：US20240353431A1

公开(公告)日：2024-10-24

申请号：US18684541

申请日：2021-08-20

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Alfred Weber ,  Herbert GRITSCH ,  Gerald SCHRENK ,  Manfred BILLWEIN ,  Andrea ENGELMAIER ,  Christopher ZLABINGER ,  Michael DOCKAL

IPC: G01N33/86

CPC classification number: G01N33/86 ,  G01N2333/755

Abstract: Described herein are methods and kits for selective and sensitive activity measurement of human coagulation factor VIII (FVIII).

公开(公告)号：US20220389479A1

公开(公告)日：2022-12-08

申请号：US17761548

申请日：2020-10-09

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Herbert Gritsch ,  Magdalena Schlager ,  Alfred Weber

IPC: C12Q1/56

Abstract: The present invention provides a heparin-insensitive assay for measuring the quantity of Factor XIa in a sample. The present invention provides a method for measuring the concentration of Factor XIa in a plasma sample by using enzymatic heparin degradation as sample pretreatment step.